Skip to Main Content

WASHINGTON — As Democrats design a way to use the government’s leverage to lower drug prices for seniors, they are facing the possibility that drug makers could try to make up their profits by hiking prices for private insurers instead.

Lawmakers in both the House and Senate are eyeing drug pricing reforms as part of a major legislative push to deliver on President Biden’s agenda this fall. A key pillar of that platform is allowing Medicare to negotiate prices with drug makers — but exactly how meaningful that policy will be is still being hammered out, according to House and Senate aides and lobbyists working on the policy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment